Dr. Kristin Higgins has been appointed Chair of the NRG Lung Cancer Committee, an esteemed role critical to guiding future clinical trials and research initiatives focused on thoracic malignancies. Dr. Higgins, a thoracic radiation oncologist at City of Hope and Chief Clinical Officer of the City of Hope Atlanta Cancer Center, brings an impressive portfolio of expertise and experience. Her longstanding involvement with NRG has been marked by impactful contributions, including her role as Principal Investigator on the pivotal NRG-LU005 phase III trial. This landmark study investigated the concurrent addition of atezolizumab, a PD-L1 immune checkpoint inhibitor, with standard-of-care chemoradiation for patients with limited-stage small cell lung cancer—a particularly aggressive subtype that historically has seen poor prognoses.

The results from NRG-LU005, presented at the 2024 American Society for Radiation Oncology (ASTRO) Plenary Session, revealed how the integration of immunotherapy with chemoradiation failed to significantly improve overall survival in this patient cohort. Despite this, the trial’s rigor and data provide critical insights that refine the direction of future immune-oncology combinations, underscoring the complexity of modulating the tumor immune microenvironment in small cell lung cancer. In addition to her clinical research acumen, Dr. Higgins holds a vital role on the NRG Board of Directors and contributes to several organizational committees, reflecting her dedication to advancing the group’s overall scientific mission.

Dr. Higgins succeeds Dr. Jeff Bradley, a leader who has been instrumental in propelling lung cancer research within NRG and globally. Dr. Bradley’s legacy as Chair is underscored by his dedication to expanding clinical trial accruals and pioneering studies that have broadly influenced thoracic oncology. His continued involvement with NRG ensures that institutional knowledge and momentum will be preserved as Dr. Higgins steps into her new role.

Parallel to the lung cancer leadership change, NRG also announced the appointment of Dr. Karthik Sundaram as the Chair of the NRG Imaging Committee. Dr. Sundaram is an Assistant Professor of Radiology specializing in abdominal imaging at the University of Pennsylvania’s Perelman School of Medicine. He brings extensive expertise in magnetic resonance imaging (MRI), ultrasound technologies, and MR-guided minimally invasive interventions, particularly in the context of prostate cancer diagnostics and therapeutics. His research primarily explores molecular imaging techniques capable of not only detecting but also predicting disease behavior at a cellular and molecular level, epitomizing the next frontier of precision oncology.

Prior to his Chair appointment, Dr. Sundaram had contributed significantly to NRG as a committee member and served as a liaison between the Imaging Committee and the Gynecologic Cancer Committee. He is actively involved as the Imaging Chair of the landmark NRG-GU012 “SAMURAI” trial, which investigates the synergy of stereotactic radiotherapy and immunotherapy in advanced renal cell carcinoma—an evolving paradigm that integrates high-precision radiation with modulated immune responses. Dr. Sundaram also spearheads grant-funded projects developing photoacoustic agents with fluorescent capabilities aimed at enhancing ovarian cancer detection and treatment. His vision is expected to further embed innovative imaging modalities into NRG’s clinical trial infrastructure.

Taking over from Dr. Daniel Pryma, who has provided invaluable leadership in incorporating advanced imaging into NRG trial designs, Dr. Sundaram is poised to reinforce the scientific rigor and translational applicability of imaging research within the organization. Dr. Pryma’s stewardship ensured that imaging considerations were integrated thoughtfully across multiple disease-specific initiatives, enabling more accurate tumor characterization, response assessment, and biomarker development.

Collectively, these leadership transitions reflect NRG Oncology’s commitment to leveraging multidisciplinary expertise to optimize clinical trial design and execution. By situating clinicians and scientists at the helm of their respective committees, the organization fosters an environment focused on translational research breakthroughs that can swiftly influence clinical practice guidelines and improve patient outcomes.

NRG Oncology, established in 2012 through the merger of three legacy cooperative groups, continues to be a powerhouse in collaborative cancer research. Its network includes over 1,300 research sites globally, primarily across North America, representing a comprehensive ecosystem of multidisciplinary investigators encompassing medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and biostatisticians. Supported primarily through grants from the NCI, NRG executes phase II and III clinical trials that challenge and redefine standards of care across numerous malignancies, emphasizing gender-specific cancers and those localized or locally advanced.

The organization’s commitment to advancing lung cancer and imaging research through these appointments promises new directions in clinical trial innovation and translational science integration. NRG’s Lung Cancer Committee, under Dr. Higgins’ guidance, will harness data-driven approaches and emerging immuno-radiotherapy combinations to address unmet clinical needs in thoracic oncology. Meanwhile, the Imaging Committee, led by Dr. Sundaram, is anticipated to advance the incorporation of cutting-edge imaging technologies and molecular probes into trial protocols, bridging the gap from bench to bedside.

Looking ahead, NRG Oncology encourages participation and leadership within the organization’s committees, inviting collaborative efforts that mobilize expertise and resources dedicated to conquering cancer through superior clinical investigation. These leadership developments underline the dynamic evolution of cancer research at NRG and its sustained influence on the clinical trial landscape.

For professionals interested in contributing to NRG Oncology’s transformative work or assuming leadership roles, current openings are accessible on the NRG website. This call to action aligns with the organization’s collaborative ethos and its vision of cultivating a robust research community committed to translational excellence and improved cancer care worldwide.

Subject of Research: Leadership appointments in lung cancer and imaging research committees within NRG Oncology and implications for clinical trials and imaging advancements in oncology.

Article Title: NRG Oncology Names New Chairs to Pioneering Lung Cancer and Imaging Committees, Driving Forward Clinical Innovation

News Publication Date: June 2024

Web References:
– https://www.nrgoncology.org/Home/News/Post/nrg-oncology-trial-implies-the-addition-of-atezolizumab-concurrently-to-standard-of-care-does-not-improve-survival-in-limited-stage-small-cell-lung-cancer
– https://open.spotify.com/episode/3Zgf3ulmPLpP5oPgxYFPDl?si=ywmGzaznTU2lM3AJ3Kiwmg
– http://www.NRGOncology.org/Current-Openings

Prostate cancer is a significant health concern, with approximately 10 million cancer-related deaths globally each year. The research team, spearheaded by Michael King from Rice University and Charles Caskey from Vanderbilt University, made remarkable strides in understanding how non-invasive FUS enhances the efficacy of TRAIL therapy. TRAIL has been recognized for its ability to specifically induce cancer cell death, offering a more targeted approach to treatment compared to conventional chemotherapy techniques. However, despite its promise, TRAIL’s clinical application has been hampered by its short half-life in circulation and suboptimal efficacy when administered alone.

A primary challenge in developing successful TRAIL therapies revolves around the protein’s rapid degradation post-administration, often requiring patients to undergo multiple treatments throughout the day. This complexity not only diminishes patient compliance but also heightens the risk of adverse side effects due to frequent dosing. The collaboration aimed to address these hurdles by exploring how mechanical forces applied through FUS could potentiate TRAIL’s therapeutic effects while mitigating its limitations.

The study’s findings reveal that low-intensity FUS generates mechanical stimuli that activate Piezo1, a mechanosensitive ion channel. The activation of Piezo1 leads to an influx of calcium ions, triggering a cascade of cellular events that culminate in cancer cell apoptosis. Importantly, this mechanism works without compromising the integrity of surrounding healthy tissues, a critical consideration in cancer therapy. This insight signifies a pivotal advancement in the ongoing quest for more effective, less invasive treatments for prostate cancer.

Utilizing prostate cancer cell lines, the research team engaged in an array of experiments to refine the operational parameters of FUS. They meticulously balanced the intensity of the ultrasound with the sensitivity of the surrounding cells, ensuring that the healthy tissues remained unharmed while maximizing the apoptotic effects on malignant cells. Their findings indicated that the synergistic combination of TRAIL and FUS vastly outperformed each agent individually, asserting the importance of this dual approach in reducing tumor volume and cellular proliferation.

King articulated the urgency of finding safe and effective therapies for advanced prostate cancer, emphasizing that the need for innovative treatments is critical given the disease ranks as the second-leading cause of cancer-related deaths among men in the United States. This study exemplifies a significant leap forward in addressing this imperative, offering a non-invasive therapeutic avenue that could soon translate into real-world clinical applications.

As physicians and researchers continue to grapple with the intricate landscape of cancer treatment, the implications of this study extend far beyond prostate cancer. The foundational insights gained may lay the groundwork for the broader application of mechanotherapy across various cancer types, hinting at the vast potential of integrating mechanical stimuli with existing pharmacological treatments. The synergy between physical force and biotherapy could herald a new era of personalized cancer care, designed to maximize therapeutic benefits while minimizing unwanted side effects.

Moreover, this research highlights the importance of interdisciplinary collaboration in tackling complex health challenges. The convergence of expertise from bioengineering and radiological sciences has yielded significant advancements in understanding cancer therapy, suggesting that future breakthroughs may rely on similar cooperative frameworks. The success of this study could inspire further innovative research efforts that integrate diverse scientific disciplines to enhance treatment outcomes for cancer patients.

In conclusion, the groundbreaking study illuminates a promising path toward an innovative therapeutic strategy for treating prostate cancer. The combination of FUS and TRAIL demonstrates not only enhanced anticancer efficacy but also signifies a non-invasive methodology that could redefine treatment paradigms in oncology. As the research community continues to advance our understanding of mechanotherapy, the hope remains that such innovative approaches will lead to improved survival rates and quality of life for countless individuals affected by cancer.

This research, funded by notable grants from the National Institutes of Health and the National Science Foundation, underscores the evolving landscape of cancer treatment and the imperative for continued innovation in therapeutic approaches.

Subject of Research: Combining TRAIL therapy with low-intensity focused ultrasound for prostate cancer treatment.

Article Title: Applying ultrasound to mechanically and noninvasively sensitize prostate tumors to TRAIL-mediated apoptosis

News Publication Date: February 21, 2025

Web References: Rice University News, Advanced Science

References: Advanced Science Journal DOI: 10.1002/advs.202412995

Image Credits: Photo by Gustavo Raskosky/Rice University

Keywords: TRAIL therapy, focused ultrasound, prostate cancer, cancer treatment, apoptosis, mechanotherapy, synergistic effect, innovative research, noninvasive therapy, cancer mortality, therapeutic strategies, biomedical engineering.

The FASCO title is awarded to members of the American Society of Clinical Oncology who exemplify exemplary dedication to the field. As highlighted in a letter from Clifford A. Hudis, M.D., the Chief Executive Officer of ASCO, the selection for this honor acknowledges the collective efforts that benefit both the society and the patients they serve. Dr. Gordon’s recognition as a FASCO showcases not just individual achievements, but also the collaborative spirit that is essential in advancing cancer care.

Mark Slater, Ph.D., Vice President of Research at HonorHealth, expressed unwavering confidence in Dr. Gordon’s contributions. He described Dr. Gordon as a dynamic force in oncology, noting how his leadership has enhanced the quality of research at the HonorHealth Research Institute. Dr. Slater provided insight into how Dr. Gordon inspires and emboldens those around him, particularly in the context of fostering an environment where advanced clinical trials can flourish.

Central to Dr. Gordon’s accomplishments is his impact on cancer patient care through innovative clinical trials. The essence of his work transcends mere research; it embodies a commitment to improving the lives of those affected by cancer. Not only does Dr. Gordon play a critical role in implementing new therapies, but he also acts as an effective ambassador for collaborations that cross-disciplinary boundaries, further enhancing the capabilities of the Institute.

Dr. Gordon’s leadership extends beyond his title as Chief Medical Officer. Since taking on the role in 2021, he has orchestrated the operations of the Research Institute’s five major divisions, which encompass areas critical to modern healthcare, including oncology and cardiovascular disease research. His roles reflect a profound understanding of the interconnectedness of medical disciplines, allowing for a holistic approach to patient care and scientific inquiry.

His dual role as a physician and researcher provides a perspective that is not only informed by scientific inquiry but also by personal experience. Having been diagnosed with early-stage pancreatic cancer in 2021, Dr. Gordon understands the patient experience on a profound level. This unique perspective drives him to push for research that not only meets scientific excellence but also prioritizes the patient’s journey across treatment modalities.

Prior to his pivotal role at HonorHealth, Dr. Gordon cultivated his expertise and network through leadership positions at prestigious institutions such as the University of Arizona Cancer Center and the Arizona Center for Cancer Care. He has engaged in extensive training at notable institutions, including Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, where he honed his skills in treating various forms of cancer. This wealth of experience has equipped him to lead with confidence and credibility in the oncology community.

Dr. Gordon’s commitment to fostering innovation within the field of oncology extends to establishing collaborations that span across the globe. His leadership and achievements in clinical research not only attract patients seeking cutting-edge treatments but also draw talented collaborators eager to advance the frontiers of cancer research and patient care.

As a recognized leader, Dr. Gordon is dedicated to enhancing the scientific community’s understanding of cancer therapies. His work encompasses a rigorous focus on developing new treatments, which holds the promise of improved outcomes for patients. Each step he takes is informed by a wealth of knowledge, a profound connection to the patient experience, and a relentless drive to push the envelope of what is possible in cancer care.

The significance of Dr. Gordon’s recognition will be formally acknowledged at the upcoming American Society of Clinical Oncology annual meeting scheduled for May 31, 2025, at McCormick Place Convention Center in Chicago. This recognition not only celebrates his past achievements but also emphasizes the ongoing importance of collaboration and innovation within the field of oncology.

Dr. Gordon’s journey is emblematic of the evolving landscape of cancer research, where physicians not only treat patients but also serve as trailblazers in the quest for innovative therapies. His work stands as a testament to the life-changing impact of medical research and the critical importance of compassionate care in all aspects of oncology.

For those within the medical and scientific community, Dr. Gordon’s recognition as a FASCO encapsulates the essence of what it means to be a dedicated physician-scientist. His story inspires future generations to pursue careers in oncology, reminding us that behind every advancement in science lies the unwavering commitment to the patient’s well-being.

As the medical community continues to evolve and the race towards innovative cancer treatments accelerates, the contributions of leaders like Dr. Gordon will undoubtedly shape the future of oncology. His title as a Fellow of ASCO is not just a personal accolade; it signifies the collective mission of all healthcare professionals striving to provide hope to patients battling cancer, underlining the importance of collaborative efforts in this formidable endeavor.

Subject of Research: Oncology Research and Development
Article Title: Michael S. Gordon, M.D.: A Leader in Oncology Research Recognized as FASCO
News Publication Date: February 6, 2025
Web References: HonorHealth Research Institute website
References: American Society of Clinical Oncology
Image Credits: HonorHealth Research Institute

Keywords: Oncology, ASCO, Cancer Research, Clinical Trials, Patient Care, Physician-Scientist, Innovation, Leadership, FASCO, Biomedical Research, Treatment Advances